Evidence map›Paper›PMID 12196602›Full record

ArticleThe Journal of neuroscience : the official journal of the Society for Neuroscience2002

Local injection of a selective endothelin-B receptor agonist inhibits endothelin-1-induced pain-like behavior and excitation of nociceptors in a naloxone-sensitive manner.

Alla Khodorova, Moin U Fareed, Alexander Gokin, Gary R Strichartz, Gudarz Davar

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of neuroscience : the official journal of the Society for Neuroscience, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
2.0field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 72 citations in OpenAlex.

  1. Article
  2. Longitudinal peripheral tissue RNA-Seq transcriptomic profiling, hyperalgesia, and wound healing in the rat plantar surgical incision model.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2021
    Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Molecular and cellular mechanisms that initiate pain and itch.Cellular and molecular life sciences : CMLS · 2015
    Review
  11. Role of renal sensory nerves in physiological and pathophysiological conditions.American journal of physiology. Regulatory, integrative and comparative physiology · 2015
    Review
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Mechanism of cancer pain.Molecular interventions · 2010
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Alla KhodorovaMolecular Neurobiology of Pain, Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women's Hospital, Boston, Massachusetts 02115, USA.
Moin U Fareed
Alexander Gokin
Gary R Strichartz
Gudarz Davar
Brigham and Women's Hospital · USHarvard University · US

Funding

Endothelin Mechanisms in Metastic Prostate Cancer PainR01CA080153 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI STRICHARTZ, GARY R · 1999 to 2014
$5.5M
Endothelin mechanisms in metastic prostate cancer painR56CA080153 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI STRICHARTZ, GARY R · 2009 to 2009
$378k
NCI NIH HHS CA 80153NCI NIH HHS R01 CA080153NCI NIH HHS R56 CA080153
6 · The paper itself

Abstract

We showed previously that subcutaneous injection of the injury-associated peptide mediator endothelin-1 (ET-1) into the rat plantar hindpaw produces pain behavior and selective excitation of nociceptors, both through activation of ET(A) receptors likely on nociceptive terminals. The potential role of ET(B) receptor activation in these actions of ET-1-has not been examined. Therefore, in these experiments, we studied the effect of blocking or activating ET(B) receptors on ET-1-induced hindpaw flinching and excitation of nociceptors in rats. An ET(B) receptor-selective antagonist, BQ-788 (3 mm), coinjected with ET-1 (200 microm) reduced the time-to-peak of flinching and significantly enhanced the average maximal flinch frequency (MFF). In contrast, coinjection of an ET(B) receptor selective agonist, IRL-1620 (100 or 200 microm), with ET-1 reduced the average MFF and the average total number of flinches. Interestingly, this unexpected inhibitory effect of IRL-1620 was prevented by the nonselective opioid receptor antagonist naloxone (2.75 mm). To confirm these inhibitory actions, we studied the effects of IRL-1620 on ET-1-induced spike responses in single, physiologically characterized nociceptive C-fibers. IRL-1620 suppressed spike responses to ET-1 in all (n = 12) C-units, with mean and maximum response frequencies of 0.08 +/- 0.02 and 1.5 +/- 0.4 impulses/sec versus 0.32 +/- 0.07 and 4.17 +/- 0.17 impulses/sec for ET-1 alone. In additional support of the behavioral results, coinjection of naloxone (2.75 mm) completely prevented this inhibitory action of IRL-1620. These results establish that ET(B) receptor activation inhibits ET-1-induced pain behavior and nociception in a naloxone-sensitive manner and point to a previously unrecognized dual modulation of acute nociceptive signaling by ET(A) and ET(B) receptors in cutaneous tissues.

Indexed as

Action PotentialsAnimalsBehavior, AnimalDose-Response Relationship, DrugDrug AntagonismDrug SynergismEndothelin-1Endothelin Receptor AntagonistsEndothelinsHindlimbInjections, SubcutaneousMaleNaloxoneNerve FibersNociceptorsOligopeptidesBQ 788Endothelin-1Endothelin Receptor AntagonistsEndothelinsNaloxoneOligopeptidesPeptide FragmentsPiperidinesReceptor, Endothelin BReceptors, Endothelinsovateltide

Identifiers

PMID12196602
PMCPMC6757974
OpenAlexW1945577104

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.